AIED
MCID: ATM021
MIFTS: 36

Autoimmune Inner Ear Disease (AIED)

Categories: Ear diseases, Rare diseases

Aliases & Classifications for Autoimmune Inner Ear Disease

MalaCards integrated aliases for Autoimmune Inner Ear Disease:

Name: Autoimmune Inner Ear Disease 20
Ocular Albinism, Type Ii 70
Aied 20

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Ear diseases


External Ids:

UMLS 70 C0268505

Summaries for Autoimmune Inner Ear Disease

MalaCards based summary : Autoimmune Inner Ear Disease, also known as ocular albinism, type ii, is related to inner ear disease and autoimmune disease. An important gene associated with Autoimmune Inner Ear Disease is MMP9 (Matrix Metallopeptidase 9), and among its related pathways/superpathways are Immune response IL-23 signaling pathway and Spinal Cord Injury. The drugs Evolocumab and Naproxen have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and bone.

Wikipedia : 73 Autoimmune inner ear disease was first defined by Dr. Brian McCabe in a landmark paper describing an... more...

Related Diseases for Autoimmune Inner Ear Disease

Diseases in the Inner Ear Disease family:

Autoimmune Inner Ear Disease

Diseases related to Autoimmune Inner Ear Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 207)
# Related Disease Score Top Affiliating Genes
1 inner ear disease 30.5 TNF TIMP1 MPO MMP9
2 autoimmune disease 30.4 TNF MPO MMP9
3 lyme disease 30.1 TNF MMP9
4 autoimmune vasculitis 30.1 TNF MPO
5 otitis media 30.0 TNF MPO
6 granulomatosis with polyangiitis 29.8 TNF MPO
7 aland island eye disease 10.8
8 sensorineural hearing loss 10.8
9 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.7
10 meniere disease 10.4
11 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
12 cogan syndrome 10.3
13 auditory system disease 10.3
14 branchiootic syndrome 1 10.3
15 pertussis 10.3
16 vasculitis 10.3
17 systemic autoimmune disease 10.3
18 labyrinthitis 10.2
19 sudden sensorineural hearing loss 10.2
20 meningitis 10.1 TNF MMP9
21 central nervous system tuberculosis 10.1 TNF MMP9
22 cardiac rupture 10.1 TNF MMP9
23 coronary aneurysm 10.1 TNF MMP9
24 heart aneurysm 10.1 TNF MMP9
25 tuberculous meningitis 10.1 TNF MMP9
26 anal fistula 10.1 TNF MMP9
27 lymphocytic colitis 10.1 TNF MMP9
28 hemorrhoid 10.1 TNF MMP9
29 periapical periodontitis 10.1 TNF MMP9
30 chronic ulcer of skin 10.1 TNF MMP9
31 blepharitis 10.1 TNF MMP9
32 transverse myelitis 10.1 TNF MMP9
33 myelitis 10.1 TNF MMP9
34 eyelid disease 10.1 TNF MMP9
35 lacrimal apparatus disease 10.1 TNF MMP9
36 diverticulitis 10.1 TNF MMP9
37 cheilitis 10.1 TNF MMP9
38 spinal cord injury 10.1 TNF MMP9
39 pyoderma 10.1 TNF MMP9
40 pyoderma gangrenosum 10.1 TNF MMP9
41 rosacea 10.1 TNF MMP9
42 gastric ulcer 10.1 TNF MMP9
43 keratoconjunctivitis 10.0 TNF MMP9
44 mononeuritis of upper limb and mononeuritis multiplex 10.0 TNF MPO
45 mononeuritis multiplex 10.0 TNF MPO
46 limb ischemia 10.0 TNF MMP9
47 aortitis 10.0 TNF MPO
48 chondromalacia 10.0 TNF MPO
49 scleroderma, familial progressive 10.0
50 lung cancer 10.0

Graphical network of the top 20 diseases related to Autoimmune Inner Ear Disease:



Diseases related to Autoimmune Inner Ear Disease

Symptoms & Phenotypes for Autoimmune Inner Ear Disease

Drugs & Therapeutics for Autoimmune Inner Ear Disease

Drugs for Autoimmune Inner Ear Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 258)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Evolocumab Approved Phase 4 1256937-27-5
2
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
3
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
4
Metronidazole Approved Phase 4 443-48-1 4173
5
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
6
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
7
Salmon calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
8
Erenumab Approved, Investigational Phase 4 1582205-90-0
9
Calcitonin gene-related peptide Investigational Phase 4 83652-28-2
10 Anticholesteremic Agents Phase 4
11 Antimetabolites Phase 4
12 Hypolipidemic Agents Phase 4
13 Lipid Regulating Agents Phase 4
14 Hormones Phase 4
15 Calcium, Dietary Phase 4
16 Vasodilator Agents Phase 4
17 Antirheumatic Agents Phase 4
18 Anti-Inflammatory Agents, Non-Steroidal Phase 4
19 Analgesics, Non-Narcotic Phase 4
20 Fibrinolytic Agents Phase 4
21 Platelet Aggregation Inhibitors Phase 4
22 Cyclooxygenase Inhibitors Phase 4
23 Antipyretics Phase 4
24 Omega 3 Fatty Acid Phase 4
25 Anti-Bacterial Agents Phase 4
26 Gastrointestinal Agents Phase 4
27 Acidophilus Phase 4
28 Anti-Infective Agents Phase 4
29 Antiparasitic Agents Phase 4
30 Antacids Phase 4
31 Anti-Ulcer Agents Phase 4
32 Antiprotozoal Agents Phase 4
33 Bismuth tripotassium dicitrate Phase 4
34 Proton Pump Inhibitors Phase 4
35 Bifidobacterium Phase 4
36
Bismuth Phase 4 7440-69-9 16682734 105143
37 Analgesics Phase 4
38 Katacalcin Phase 4
39 calcitonin Phase 4
40
Calcium Nutraceutical Phase 4 7440-70-2 271
41
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
42
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
43
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
44
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
45
Sodium citrate Approved, Investigational Phase 3 68-04-2
46
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
47
Atorvastatin Approved Phase 3 134523-00-5 60823
48
Aztreonam Approved Phase 3 78110-38-0 5362041 5742832
49
Adalimumab Approved, Experimental Phase 3 331731-18-1 16219006
50
Rilonacept Approved, Investigational Phase 3 501081-76-1 104924

Interventional clinical trials:

(show top 50) (show all 327)
# Name Status NCT ID Phase Drugs
1 Tocilizumab Real-Life Human Factors Validation Study Completed NCT02682823 Phase 4 Tocilizumab
2 Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption? Completed NCT00766532 Phase 4 Aromatase Inhibitor
3 A Randomized Controlled Trial Comparing the Efficay and Tolerability of Ai Chi Versus Stretching in Fibromyalgia Management: a Six Months Study Completed NCT00600574 Phase 4
4 Pool-based Exercise in Fibromyalgia Management: a Prospective Randomized Comparison Between Stretching and Ai Chi Completed NCT00550641 Phase 4
5 A Multicenter, Open-label, Single-arm, Study to Evaluate Safety and Tolerability of Repatha in Patients With Homozygous Familial Hypercholesterolemia (HoFH) in India Completed NCT03403374 Phase 4 evolocumab
6 A Study to Assess the Effect and Safety of Artificial Intelligence Assisted Insulin Titration System on Glucose Control in Type 2 Diabetes Mellitus Patients: A Single-center, Open-labeled, Parallel, Randomized Controlled Trial Completed NCT04053959 Phase 4 AI assisted insulin system;Physician based insulin regime
7 Project 1: Program on Genetic and Dietary Predictors of Drug Response in Rural and AI/AN Populations (Naproxen Study) Recruiting NCT04449471 Phase 4 Naproxen tablet
8 Biomarker and Genetic Predictors of Erenumab Treatment Response, a Phase 4 Investigational Open-label Study (INTERROGATE) Recruiting NCT04265755 Phase 4 Erenumab
9 Registry for Migraine - Structural and Functional Magnetic Resonance Imaging Before and After Erenumab Treatment Recruiting NCT04674020 Phase 4 Erenumab
10 Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab Recruiting NCT04592952 Phase 4 Calcitonin Gene-Related Peptide;Erenumab
11 Early-phase Schizophrenia: Practice-based Research to Improve Outcomes (ESPRITO) - Using Artificial Intelligence to Measure Adherence to Oral Medication Recruiting NCT04046497 Phase 4
12 Registry for Migraine - Clinical Core Recruiting NCT04603976 Phase 4 Erenumab
13 Program on Genetic and Dietary Predictors of Drug Response in Rural and AI/AN Populations, Project-3, SA-3, Anti-platelet Response Active, not recruiting NCT04456608 Phase 4 Aspirin
14 The Studies of Integrating Gastric and Gut Microbiota, F. Prausnitzii Metabolites, Microenvironment, and Epigenetics to Identify the Cancer Risk of H. Pylori-related Precancerous Conditions Through an AI System and Control the Risky by Probiotic Supplements Enrolling by invitation NCT04527055 Phase 4 Bismuth Subcitrate
15 Phase 4, Open-label Study to Evaluate Treatment Satisfaction With Erenumab in Patients With Migraine Not yet recruiting NCT04825678 Phase 4 Erenumab
16 Very High Power Ablation in Patients With Atrial Fibrillation Scheduled for a First Pulmonary Vein Isolation: the POWER-PLUS Study Not yet recruiting NCT04784013 Phase 4
17 A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer Unknown status NCT00382070 Phase 3 Letrozole
18 Aromatase Inhibitors (AI) Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Treatment in Postmenopausal Hormone Receptor-positive Breast Cancer Unknown status NCT02769104 Phase 3 Letrozole (Aromatase Inhibitors);AC*4-T*4
19 Preventing Stroke Triggers in Children With Sickle Cell Anaemia in Mulago Hospital, Kampala (PREST ): a Randomized Control Trial Unknown status NCT03666806 Phase 2, Phase 3
20 Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents Unknown status NCT00111345 Phase 2, Phase 3 Anthracyclines;liposomal daunorubicin;2-CDA;AI
21 MAINtenance Afinitor: A Randomized Trial Comparing Maintenance Aromatase Inhibitors (AIs) + Everolimus (Afinitor) vs AIs in Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients With Disease Control After First Line Chemotherapy Completed NCT02511639 Phase 3 Everolimus;Aromatase Inhibitors
22 Comparative Clinical Study of Ultrasound-Guided A1 Pulley Release vs Open Surgical Intervention in the Treatment of Trigger Finger Completed NCT02830672 Phase 2, Phase 3
23 A Multicenter, Randomized, Open-label, Parallel-group Usability Study of the Commercial 1 mL Alirocumab Auto-injector Device (AI) and the New 2 mL Auto-injector Device (SYDNEY) in High or Very High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy Completed NCT03415178 Phase 3 Alirocumab SAR236553;Atorvastatin;Rosuvastatin
24 A Phase 3, International, Exploratory, Open-Label, Multicenter, Dual-Injection, Echocardiographic Imaging Settings and Safety Study of AI-700 in Normal Volunteers and Stable Cardiac Patients Completed NCT00669851 Phase 3 AI-700
25 Improving Low Bone Mass With Vibration Therapy for Girls With Adolescent Idiopathic Scoliosis (AIS) - A Randomized Controlled Trial Completed NCT01108211 Phase 3
26 An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Completed NCT02722044 Phase 3
27 IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs Completed NCT00288704 Phase 3 rilonacept 160 mg;Placebo;rilonacept 160 mg
28 A Phase 3, International, Multicenter, Open Label, Dual-Injection, Echocardiographic Imaging and Safety Study of AI-700 in Patients With Suspected Ischemic Heart Disease Undergoing Single-Photon Emission Computed Tomography (Real-Time Assessment of Myocardial Perfusion With Echocardiography: RAMP 1) Completed NCT00156793 Phase 3
29 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
30 Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia Administered to Patients With High-Risk Sarcoma Receiving Intensive Chemotherapy (Adriamycin and Ifosfamide (AI)) Completed NCT00038311 Phase 3 PN-152,243)/PN-196,444
31 A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica. Completed NCT00128661 Phase 3
32 A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) vs. Exemestane (AROMASIN™) in Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer With Disease Progression After Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy Completed NCT00065325 Phase 3 Fulvestrant;Exemestane
33 A Phase 3, Open-label, Follow-On Study of Multiple Courses of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients (AIR-CF3) Completed NCT00128492 Phase 3 AZLI 75 mg two times a day (BID)/ three times a day (TID)
34 A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women With Osteoporosis to Evaluate the Noninferiority of Subject-administered Romosozumab Via Autoinjector/Pen vs Healthcare Provider-administered Romosozumab Via Prefilled Syringe Completed NCT03432533 Phase 3 romosozumab HCP administration with PFS
35 Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation Completed NCT01044862 Phase 3 Letrozole (aromatase inhibitor);Clomiphene Citrate;Follicle Stimulating Hormone (gonadotropin)
36 A Multicenter, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia to Assess Subjects' Ability to Administer a Full Dose of Evolocumab (AMG 145) in Home-use, Using Either a 3.5 mL Personal Injector or a Prefilled Autoinjector/Pen. Completed NCT01879319 Phase 3
37 A Multicenter, Randomized, Open-label, Parallel Group, Functionality, and Performance Study of an Accessorized Pre-filled Syringe and Autoinjector With Home-administered Subcutaneous Tezepelumab in Adolescent and Adult Subjects With Severe Asthma (PATH-HOME) Completed NCT03968978 Phase 3
38 A Multicenter, Randomized, Comparative Study Regarding the Efficacy of Denosumab on Normal Bone Mineral Density in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer (ENDEAVOR Trial) Recruiting NCT03324932 Phase 3 Denosumab Injection
39 Randomized Trial of Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With Estrogen Receptor-Positive HER2 Negative Breast Cancer Recruiting NCT02535221 Phase 3 Goserelin+TAM+AI;Epirubicin+CTX+5-Fu
40 A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy Recruiting NCT04353492 Phase 3
41 A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis Recruiting NCT04333147 Phase 3 csDMARD(s)
42 A Phase III Trial to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus an Aromatase Inhibitor (AI) vs. Trastuzumab Plus an AI vs. Lapatinib Plus an AI as 1st- or 2nd- Line Therapy in Postmenopausal Subjects With Hormone Receptor+, HER2-positive Metastatic Breast Cancer (MBC) Who Received Prior Trastuzumab and Endocrine Therapies Active, not recruiting NCT01160211 Phase 3 lapatinib;trastuzumab;Aromatase inhibitor;lapatinib
43 A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-011) Active, not recruiting NCT01729754 Phase 3 Tildrakizumab 200 mg;Tildrakizumab 100 mg;Tildrakizumab Placebo;Etanercept Placebo;Etanercept 50 mg
44 Trial of Perioperative Endocrine Therapy - Individualising Care Active, not recruiting NCT02338310 Phase 3 Aromatase Inhibitors
45 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Addition to Optimal Stable Background Statin Therapy in Chinese Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia Terminated NCT03433755 Phase 3 Evolocumab 140 mg SC Q2W;Evolocumab 420 mg SC QM
46 A Phase III Randomized, Double Blind, Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTOR Inhibitor Based Treatment Terminated NCT01633060 Phase 3 Fulvestrant;BKM120;BKM120 matching placebo
47 Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy Unknown status NCT01613560 Phase 2 AI adjuvant therapy;AI+chemotherapy adjuvant therapy;AI adjuvant therapy
48 A Phase II Study of the Efficacy and Tolerability of Bicalutamide Plus Aromatase Inhibitors in Estrogen Receptor(+)/Androgen Receptor(+)/HER2(-) Metastatic Breast Cancer Unknown status NCT02910050 Phase 2 Bicalutamide;Aromatase Inhibitor
49 An Open-label Study of the Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease Completed NCT01950312 Phase 2 gevokizumab
50 A Phase I/II Open-label Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease Completed NCT01267994 Phase 1, Phase 2 Anakinra

Search NIH Clinical Center for Autoimmune Inner Ear Disease

Genetic Tests for Autoimmune Inner Ear Disease

Anatomical Context for Autoimmune Inner Ear Disease

MalaCards organs/tissues related to Autoimmune Inner Ear Disease:

40
Skin, Breast, Bone, Spinal Cord, Lung, Brain, Heart

Publications for Autoimmune Inner Ear Disease

Articles related to Autoimmune Inner Ear Disease:

(show top 50) (show all 185)
# Title Authors PMID Year
1
The Pathogenesis of secondary forms of Autoimmune Inner Ear Disease (AIED): advancing beyond the audiogram data. 61
33476250 2021
2
Autoimmune Inner Ear Disease among Patients with Selective IgA Deficiency. 61
33311024 2021
3
Cochlear Implantation as a Treatment for Sudden Autoimmune Sensorineural Hearing Loss in a Patient Affected by Eosinophilic Granulomatosis with Polyangiitis: A Case Report and A Review of Literature. 61
32613850 2021
4
Autoimmune inner ear disease: A systematic review of management. 61
33364414 2020
5
Unilateral autoimmune inner ear disease in a patient with lung cancer treated with nivolumab. 61
32995031 2020
6
Cochlear Implant Performance in Adult Patients with Absent Intraoperative Electrically Evoked Compound Action Potentials. 61
32122228 2020
7
Autoimmune inner ear disease patient-associated 28-kDa proinflammatory IL-1β fragment results from caspase-7-mediated cleavage in vitro. 61
32051334 2020
8
An update on autoimmune inner ear disease: A systematic review of pharmacotherapy. 61
31733712 2020
9
Demystifying autoimmune inner ear disease. 61
31605190 2019
10
Pediatric Autoimmune Inner Ear Disease: A Rare, But Treatable Condition. 61
31609997 2019
11
miR‑10b‑3p, miR‑8112 and let‑7j as potential biomarkers for autoimmune inner ear diseases. 61
31115534 2019
12
Emerging options in immune-mediated hearing loss. 61
30828626 2019
13
Fluctuating Sensorineural Hearing Loss. 61
31315108 2019
14
Ear Involvement in Inflammatory Bowel Disease: A Review of the Literature. 61
29977417 2018
15
Imaging in autoimmune inner-ear disease and endolymphatic hydrops, bone cement for improving hearing outcomes in stapes surgery, and the reporting of results. External ear canal cholesteatoma: a hypothesis. 61
30019670 2018
16
The Clinician Faced With Anticochlear Antibodies: What to Do With Them? 61
29116948 2018
17
Autoimmune inner ear disease (AIED): A diagnostic challenge. 61
30376736 2018
18
Update on Vertigo in Autoimmune Disorders, from Diagnosis to Treatment. 61
30356417 2018
19
Autoimmune inner ear disease secondary to Hashimoto's thyroiditis: a case report. 61
30181832 2018
20
Autoimmune Inner Ear Disease: Immune Biomarkers, Audiovestibular Aspects, and Therapeutic Modalities of Cogan's Syndrome. 61
29850616 2018
21
Bilateral Vestibular Weakness. 61
29904366 2018
22
Evaluation and Treatment of Acute and Subacute Hearing Loss: A Review of Pharmacotherapy. 61
29023930 2017
23
The Balance of Tissue Inhibitor of Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Autoimmune Inner Ear Disease Patients. 61
28696822 2017
24
Mobile tablet audiometry in fluctuating autoimmune ear disease. 61
28270231 2017
25
Autoimmune Ear Disease: Clinical and Diagnostic Relevance in Cogan's Sydrome. 61
28458810 2017
26
Cochlear Impairment and Autoimmune Ear Disorder in a Patient with Breast Cancer. 61
28458811 2017
27
AAO: Autoimmune and Autoinflammatory (Disease) in Otology: What is New in Immune-Mediated Hearing Loss. 61
27917401 2016
28
Autoimmune sensorineural hearing loss as presenting manifestation of paediatric Behçet disease responding to adalimumab: a case report. 61
27600159 2016
29
Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. 61
26885370 2016
30
Altered Brain Glucose Consumption in Cogan's Syndrome. 61
28050276 2016
31
Immune-mediated cochleovestibular disease. 61
26830038 2016
32
Systematic Review of Treatments for Autoimmune Inner Ear Disease. 61
26485595 2015
33
N-Acetylcysteine attenuates tumor necrosis factor alpha levels in autoimmune inner ear disease patients. 61
26392121 2015
34
Current understanding of the pathogenesis of autoimmune inner ear disease: a review. 61
25847404 2015
35
Complications in a series of 4400 paediatric cochlear implantation. 61
26139509 2015
36
Treatment of Menière's Disease. 61
25749846 2015
37
Diffuse systemic sclerosis presenting as Meniere's disease-like symptoms as part of autoimmune inner ear disease. 61
26040060 2015
38
Goodpasture's syndrome: a clinical update. 61
25462583 2015
39
Progression of autoimmune inner ear disease to labyrinthitis ossificans: clinical and radiologic correlation. 61
25738715 2015
40
Vestibular evoked myogenic potentials in patients with rheumatoid arthritis. 61
26478874 2015
41
Paraneoplastic syndrome: a masquerade of autoimmune inner ear disease. 61
25427223 2015
42
Cochlin in autoimmune inner ear disease: is the search for an inner ear autoantigen over? 61
25199741 2014
43
An open label study to evaluate the safety and efficacy of intratympanic golimumab therapy in patients with autoimmune inner ear disease. 61
25203561 2014
44
Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease. 61
25133431 2014
45
IL-1β inhibition in autoimmune inner ear disease: can you hear me now? 61
25133418 2014
46
New prospects in the diagnosis and treatment of immune-mediated inner ear disease. 61
25332908 2014
47
Mining immune epitopes in the inner ear. 61
24367049 2014
48
A critical role for interleukin-1β in the progression of autoimmune diseases. 61
24012439 2013
49
Infliximab for autoimmune inner ear disease: case report and literature review. 61
24125068 2013
50
Innate immune recognition of molds and homology to the inner ear protein, cochlin, in patients with autoimmune inner ear disease. 61
23912888 2013

Variations for Autoimmune Inner Ear Disease

Expression for Autoimmune Inner Ear Disease

Search GEO for disease gene expression data for Autoimmune Inner Ear Disease.

Pathways for Autoimmune Inner Ear Disease

Pathways related to Autoimmune Inner Ear Disease according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.11 TNF TIMP1 MPO
2 11.62 TNF MMP9
3 11.59 TNF MPO
4 11.56 TNF MMP9
5 11.49 TNF TIMP1 MMP9
6 11.44 TIMP1 MMP9
7
Show member pathways
11.33 TNF TIMP1 MMP9
8
Show member pathways
11.28 TNF MMP9
9 11.24 TIMP1 MMP9
10 11.12 TNF TIMP1
11 10.93 TNF TIMP1 MMP9
12 10.77 TIMP1 MMP9
13 10.53 TNF MPO
14 10.48 TNF MPO MMP9

GO Terms for Autoimmune Inner Ear Disease

Cellular components related to Autoimmune Inner Ear Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.26 TNF TIMP1 MPO MMP9
2 extracellular space GO:0005615 8.92 TNF TIMP1 MPO MMP9

Biological processes related to Autoimmune Inner Ear Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.43 TIMP1 MPO MMP9
2 response to organic substance GO:0010033 9.37 TNF TIMP1
3 extracellular matrix disassembly GO:0022617 9.32 TIMP1 MMP9
4 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.16 TNF MMP9
5 cytokine-mediated signaling pathway GO:0019221 9.13 TNF TIMP1 MMP9
6 cellular response to UV-A GO:0071492 8.62 TIMP1 MMP9

Molecular functions related to Autoimmune Inner Ear Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 8.62 TNF TIMP1

Sources for Autoimmune Inner Ear Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....